132 results about "Cell lymphoma" patented technology

The invention is applicable to the technical field of clinical medicine, provides a clinical multi-modal cancer drug response prediction method based on feature reconstruction, constructs a clinical multi-modal model for drug response prediction of diffuse large B-cell lymphoma, and aims to predict the drug response of diffuse large B-cell lymphoma by integrating gene sequencing and clinical multi-modal data. And accurate drug reaction prediction is realized. The model adopts an end-to-end multi-stage processing flow: firstly, extracting gene features through TransP-Net, and processing multi-modal clinical data by using a clinical information encoder; then, pseudo-gene features are generated through a clinical-genome filling module to deal with the data missing problem; and finally, multi-modal deep fusion is realized through a clinical information decoder, and a prediction result is output. According to the method, data characteristics and working processes in a real clinical environment are fully considered, two conditions of complete gene data and missing gene data can be processed at the same time, and the method has a good clinical transformation prospect and application value.

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention relates to the technical field of biomedicine, in particular to a molecular target for treating recurrent refractory diffuse large B-cell lymphoma and application of the molecular target. According to the invention, a molecular target CSNK1E for treating recurrent refractory diffuse large B-cell lymphoma is excavated; compared with existing traditional targets of other drugs for recurrent lymphoma, the CSNK1E has a remarkable expression difference in the recurrent DLBCL, and it is indicated that the CSNK1E possibly has more remarkable advantages in treatment of the recurrent DLBCL.

Disclosed herein are synthetic nanoparticles, pharmaceutical compositions, kits, or methods for treating and / or preventing cancer. In some embodiments, the synthetic nanoparticles and / or pharmaceutical compositions comprises a pH sensitive liposome, an apolipoprotein, and andrographolide or derivative thereof. In some embodiments, the synthetic nanoparticles are delivered to a subject for treatment of cancer. In some embodiments, the cancer is T-cell lymphoma or B-cell lymphoma.

The present invention relates to anti-CD 103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases. Also disclosed is an imaging agent comprising the anti-CD 103 antibody and a detectable label, wherein the antibody either does not block CD 103 binding to E-cadherin or at least partially blocks CD 103 binding to E-cadherin. The methods of treatment involve administering the anti CD 103 antibody which may be optionally coupled to a cytotoxic agent. Diseases to be treated include e.g. Hairy Cell leukemia, HCLv, intestinal and extraintestinal lymphomas, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Sezary Syndrome (SS), Alzheimer's disease, Parkinson's disease or multiple sclerosis.

The application provides use of a compound A or a pharmaceutically acceptable salt thereof as a Bruton's tyrosine kinase (BTK) inhibitor in preparation of a drug for treating a BTK-related tumor disease. In vitro and in vivo test results show that the compound A has good inhibitory activity on BTK kinase, good inhibitory activity on human B-cell lymphoma cells with high BTK expression, and good in vivo anti-tumor activity. In addition, the compound A has good pharmacokinetic properties and metabolic stability, and can be used for developing a drug preparation for treating a BTK-related tumor disease, and has important clinical application value.

The present disclosure relates generally to mutations in T cell lymphoma, and methods of use of the mutations in T cell therapy.

This disclosure provides a method for treating lymphoma, the method comprising administering a bispecific CD20xCD3 antibody to a patient in need, wherein the patient is selected based on an improvement in the level of circulating tumor (ct) DNA. In some embodiments, this disclosure provides a method for identifying lymphoma patients who may respond well to a therapy comprising a bispecific CD20xCD3 antibody.

The application discloses an index combination for identifying diffuse large B-cell lymphoma and application thereof. The index combination is composed of gender, age and eight oligosaccharide chains, namely NGA2F, NG2FB, NG1A2F-1, NG1A2F-2, NA2F, NA2FB, NA3Fb and NA4Fb. The application also provides a prediction model, a prediction system, a computer readable storage medium and a kit constructed based on the index combination. Experimental results show that the prediction model has a sensitivity of 88.06%, a specificity of 92.98% and an AUC of 0.949 in identifying diffuse large B-cell lymphoma in a verification set. The application realizes, for the first time, non-invasive, rapid and high-accuracy identification of diffuse large B-cell lymphoma based on blood oligosaccharide chains combined with clinical indexes, and provides a brand-new tool for auxiliary differential diagnosis of patients with lymph node enlargement.

The invention relates to the technical field of biological medicines, in particular to a polypeptide targeting B cell lymphoma cells, a targeting effect conjugate and application of the polypeptide and the targeting effect conjugate. Wherein the peptide chain length of the polypeptide targeting the B-cell lymphoma cells is 12 amino acids, and the polypeptide is selectively and specifically combined with the B-cell lymphoma cells. The targeting effect conjugate is formed by connecting polypeptide and pro-apoptotic peptide through a connecting peptide. The pro-apoptotic peptide can induce programmed death of target cells by destroying a mitochondrial membrane structure. The molecular weight of the polypeptide is small, the chemical synthesis process is simple, convenient and efficient, high consistency between different batches of products can be ensured in the synthesis process, and a guarantee is provided for subsequent quality control. The small molecular structure is also convenient for sequence optimization and terminal modification, can create extremely favorable conditions for subsequent structure-function relationship research and pharmaceutical development work, and is helpful for accelerating the research and development process of novel therapeutic drugs.

The present disclosure relates to anti-CD79b antibodies and anti-CD79b antibody drug conjugates (anti-CD79b ADCs) comprising thereof, where the anti-CD79b ADCs further comprise a topoisomerase 1 inhibitor (Top1i) drug as a payload. The present disclosure further relates to methods of using such anti-CD79b ADCs for treating B-cell non-Hodgkin lymphoma (B-NHL), diffuse large B cell lymphoma (DLBCL), Burkitt's lymphoma, mantle cell lymphoma, and follicular lymphoma.

This invention relates to the field of molecular diagnostics, specifically providing a diagnostic kit for the combined detection of DLBCL based on plasma exosomal miRNAs. This invention provides two or more peripheral blood exosomes used as diagnostic biomarkers for diffuse large B-cell lymphoma (DLBCL). Based on these DLBCL diagnostic biomarkers, this invention also provides a non-invasive, highly reproducible, and highly specific plasma exosomal miRNA diagnostic kit for the early diagnosis and follow-up monitoring of DLBCL. The plasma exosomal miRNA diagnostic kit provided by this invention is of great significance in the early diagnosis, genotyping, relapse monitoring, and efficacy evaluation of DLBCL.

The application discloses Lactobacillus reuteri and application thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, and relates to the technical field of biological medicine. The application provides application of Lactobacillus reuteri and / or a metabolite thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, wherein the Lactobacillus reuteri is Lactobacillus reuteri (HG001). Limosilactobacillus reuteri The Lactobacillus reuteri is separated from feces of healthy people and used for preparation of the medicine for treating diffuse large B-cell lymphoma, and it is found that the Lactobacillus reuteri is confirmed as a probiotic strain for enhancing the chemotherapy effect of diffuse large B-cell lymphoma and can improve side effects caused by cyclophosphamide treatment of diffuse large B-cell lymphoma; and the Lactobacillus reuteri and the cyclophosphamide have a synergistic effect in treatment of diffuse large B-cell lymphoma.

Described are the compounds, compositions and methods of treating a disease or disorder characterized by aberrant B-cell lymphoma 6 (BCL6) activity.

This invention relates to the field of tumor molecular biology, specifically providing the application of targeting the ISG15 protein in chemotherapy sensitization drugs and prognostic assessment for B-cell lymphoma. This invention also provides the use of the ISG15 protein as a biomarker in the preparation of prognostic assessment products for B-cell lymphoma. This invention effectively reverses chemotherapy-induced senescence-related drug resistance and restores the chemosensitivity of tumor cells by inhibiting the ISG15 pathway; simultaneously, the ISG15 expression level can serve as a biomarker for prognostic assessment of B-cell lymphoma. This invention provides a new technical solution for overcoming chemotherapy resistance in B-cell lymphoma and assessing patient prognosis.

The invention discloses a method for screening a B-cell lymphoma biomarker, and belongs to the technical field of bioinformatics. The invention aims to provide a more accurate and simple method for screening the B-cell lymphoma biomarker. The invention provides a method for screening a B cell lymphoma biomarker. The relation between the infiltration ratio of all cell subgroups of T / NK and myeloid cells and the lifetime of a patient is screened out by utilizing scRNA-seq data of Burki lymphoma, diffuse large B cell lymphoma, follicular lymphoma and spleen marginal region lymphoma and bulk RNA-seq data of a Burki lymphoma and diffuse large B cell lymphoma database. And a theoretical basis is provided for screening survival analysis of lymphoma diseases.

Provided is a method for diagnosing the prognosis and therapeutic effect for chemotherapy in patients with rheumatoid arthritis-associated lymphoproliferative disorder (RA-LPD), who have developed a lymphoproliferative disorder (LPD) during the treatment of rheumatoid arthritis (RA). This is a kit for diagnosing the prognosis and therapeutic effect for chemotherapy in rheumatic arthritis-associated lymphoproliferative disorder (RA-LPD) patients, who have developed LPD during RA treatment. The kit comprises: means for detecting an inositol 1,4,5-triphosphate receptor (ITPR) type 2 (ITPR2) gene mutation in a biological sample from a patient; and instructions for determining that the prognosis and therapeutic effect for chemotherapy are poor when an ITPR2 gene mutation is present in the biological sample from the patient. The LPD is diffuse large B-cell lymphoma (DLBCL). For the ITPR2 gene mutation, Chr12:rs26744460 is GT or GG. Use for the diagnosis of non-RA lymphoma patients is also possible.

The application discloses a kind of bispecific anti-CD3 / CD20 antibodies and its application in B cell lymphoma, belong to the field of biological medicine technology.The bispecific antibody uses "tandem type" molecular structure, by the single-chain antibody (scFv) of anti-CD20 and the nanometer antibody (VHH) of anti-CD3 are fused by flexible connecting peptide.The high-purity bispecific antibody BsAb-20S3V is obtained by CHO cell stable expression system, and it has nanomolar level affinity to CD20+ and CD3+ cells.Experiments in vitro prove that the antibody can effectively mediate T cell specific killing to Raji cell, and the maximum killing rate can reach 75%-90%.In vivo pharmacodynamic evaluation shows that in tumor-bearing mouse model, high-dose group can significantly inhibit tumor growth and induce tumor negative growth.The antibody has good potential to prepare B cell lymphoma treatment drugs.

The present disclosure relates generally to mutations in B cell lymphoma, and methods of use of the mutations in T cell therapy.

To provide a composition and method for treating T-cell lymphoma and T-cell leukemia.SOLUTION: A method for treating cancer includes the steps of: administering a first modified cell including a chimeric antigen receptor (CAR) including an antigen-binding domain, a transmembrane domain and an intracellular domain to a subject; and administering a second modified cell, in which an endogenous CD5 gene is knocked out, to the subject. It is preferable that the antigen-binding domain be an antigen-binding domain that can be bound to CD2, CD5 or CD7, and it is preferable that the endogenous CD5 gene be knocked out by a CRISPER / Cas9 method.SELECTED DRAWING: Figure 1

Described herein are certain quinoline carboxamides for use in the treatment of myeloproliferative tumors (MPNs). Said quinoline carboxamides, optionally in combination with an additional compound selected from the group consisting of Janus kinase (JAK) inhibitors, bromodomains and terminal exo-motif protein (BET) inhibitors, B cell lymphoma 2 (Bcl-2) inhibitors, and combinations thereof, can more specifically be used for the treatment of advanced MPNs, including accelerated MPNs and secondary acute myeloid leukemia, such as acute myeloid leukemia. , acute myelogenous leukemia evolved from a previous myeloproliferative tumor (AML after MPN). Also included are pharmaceutical combinations of the quinoline carboxamide and a second agent, such as a BET inhibitor or a Bcl-2 inhibitor. Also included are certain quinoline carboxamides for use in the treatment of myeloproliferative tumors (MPN) in combination with a BET inhibitor or a Bcl-2 inhibitor.

The invention provides a B cell lymphoma prognostic risk layered prediction method and device, and relates to the technical field of biological information. The prediction method comprises the following steps: acquiring clinical examination data and BCR immune repertoire sequencing data of a to-be-predicted object; extracting a prognosis key feature set, inputting the prognosis key feature set into the risk hierarchical model, and performing clustering analysis on feature distribution of the to-be-predicted object; and determining a prognosis risk layering level of the to-be-predicted object according to an output result of the clustering analysis. According to the method, multi-dimensional key features of clinical and BCR immune repertoire are fused, and the Gaussian mixture model is utilized to perform probability clustering on complex biological data, so that the defect of insufficient discrimination of traditional hard stratification is effectively overcome, different risk subgroups are accurately identified, and the accuracy and clinical guidance value of prognosis evaluation of B-cell lymphoma are remarkably improved.

The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

The present invention relates to methods of treating B-cell lymphomas, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20 / anti-CD3 bispecific antibody (e.g., glofitamab) and in combination with one or more anti-CD20 antibodies (e.g., obinutuzumab and / or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and / or etoposide.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).

The present invention relates to methods of treating previously untreated diffuse large B-cell lymphoma (DLBCL), which is defined as high risk according to circulating tumor DNA (ctDNA), by administering gphentumab and in combination with chemotherapy.

This invention relates to the field of biotechnology, specifically to compositions and their application in the preparation of drugs for the prevention and treatment of lymphoma. The invention provides a composition comprising clostridium tumefaciensin and epipitorone, which synergistically enhance the effects of targeting the LCP2-mediated IQGAP2 / LaminA / C / SUV39H1 axis to combat chemotherapy resistance in NK / T cell lymphoma. The combined use of these two drugs can significantly reverse chemotherapy resistance, providing a new treatment strategy and drug combination for relapsed / refractory NKTCL. Experimental comparisons of the efficacy of immunotherapy drugs such as PD-1 inhibitors revealed that the anti-cellular senescence drug combination of clostridium tumefaciensin and epipitorone provided by this invention is significantly more effective than PD-1 inhibitors.

The invention relates to the technical field of disease prognosis and molecular biology, in particular to application of immune-related polygenes in prognosis evaluation of diffuse large B-cell lymphoma. The biomarkers are DES, CHIT1, FGF14, CCR4, CTLA4 and VGF (Vertical Growth Factor). According to the method, core genes related to immunity are screened on the basis of diffuse large B cell lymphoma transcriptome data such as GEO and TCGA, and a multi-gene immune model: RS = (-0.0306) * DES + (-0.4683) * CHIT1 + (1.1418) * FGF14 + (0.1132) * CCR4 + (-0.07) * CTLA4 + (-0.3463) * VGF is constructed; according to the immune polygene immune model, diffuse large B-cell lymphoma patients can be divided into high and low RS groups, the survival prognosis of high-RS people is proved to be obviously lower than that of low-RS people, and the survival prognosis can be used as an independent prognosis index.